NCT04860687 (ODISSEA) is a clinical trial in Covid19, sponsored by Azienda Sanitaria-Universitaria Integrata di Udine.

Who is sponsoring NCT04860687?

NCT04860687 is sponsored by Azienda Sanitaria-Universitaria Integrata di Udine.

What condition does NCT04860687 study?

NCT04860687 studies Covid19, Post Traumatic Stress Disorder, Quality of Life.

Is NCT04860687 still recruiting?

NCT04860687 is currently status unknown. Last updated 7 October 2021.

Last reviewed 2021-10-07 · How we verify

NCT04860687: ODISSEA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the ODISSEA Study.

Status unknown Last updated 7 October 2021

What this trial tests

trial in Covid19 in 309 participants. Status unknown.

Timeline

1 August 2021

Primary endpoint
30 November 2021

31 December 2021

Quick facts

Lead sponsor	Azienda Sanitaria-Universitaria Integrata di Udine
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	309
Start date	1 August 2021
Primary completion	30 November 2021
Estimated completion	31 December 2021
Sites	8 locations across Italy

Conditions studied

Covid19 — all drugs for Covid19 →
Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
Quality of Life — all drugs for Quality of Life →

Sponsor

Azienda Sanitaria-Universitaria Integrata di Udine — full company profile →

Who can join

Adults 18 to 99, any sex, with Covid19 or Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute respiratory insufficiency is one of the principal causes of intensive care admission for COVID 19 positive patients. This may determine a variable mortality rate ranging from 25-30%. In these patients, many days of non-invasive or invasive mechanical ventilation are needed to correct severe hypoxemia. Mechanical ventilation is not a direct therapy but allows the clinicians to prolong the "time-to-recovery" interval necessary for COVID 19 respiratory insufficiency treatment. Long intensive care stay, mechanical ventilation, the use of steroids and sedatives have an impact on the survivors. Previous studies demonstrated that patients admitted to intensive care with non-COVID acute respiratory distress syndrome had a reduction in the quality of life even up to one year after discharge. The aim of this study is to understand if COVID-19 related acute respiratory distress syndrome has a worse impact on the quality of life one year after discharge when compared with non-COVID-19 acute respiratory distress syndrome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Quality of Life in COVID-Related ARDS Patients One Year after Intensive Care Discharge (Odissea Study): A Multicenter Observational Study.
Deana C, Vetrugno L, Cortegiani A, Mongodi S, et al · · 2023 · cited 26× · PMID 36769705 · DOI 10.3390/jcm12031058
Quality of life 1 year after hospital discharge in unvaccinated pregnant women with COVID-19 respiratory symptoms: a prospective observational study (ODISSEA-PINK study).
Vetrugno L, Sala A, Deana C, Meroi F, et al · · 2023 · cited 4× · PMID 37746068 · DOI 10.3389/fmed.2023.1225648

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Azienda Sanitaria-Universitaria Integrata di Udine trials

Trials by the same sponsor.

NCT06750003 — 4K Versus 3D Total Laparoscopic Bilateral Oophorectomy: Tools in Comparison · NA · not yet recruiting
NCT06443736 — TRESPASS Clinical Study · NA · recruiting
NCT06100926 — Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain · NA · enrolling by invitation
NCT05914454 — Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome · Phase 2 · unknown
NCT05526573 — Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04860687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Sanitaria-Universitaria Integrata di Udine
Last refreshed: 7 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04860687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing